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The evolution of enabling technologies and their associated 
perspectives into molecular mechanisms underlying disease has extended 
beyond the abilities of scientific and clinical structures to advance their 
translation into new algorithms that improve the health of patients and 
populations.1 Research programs have yielded a vast array of novel 
molecules related to pathophysiological mechanisms that represent 
diagnostic and therapeutic targets which have the potential for 
personalized healthcare management. Yet, despite extraordinary 
scientific advances, routine successful translation of discovery into new 
therapeutic tools remains a distant vision. Beyond constraints in bridging 
discovery science with clinical translation due to obstacles in facilities, 
resources and in skilled specialized investigators, 95% of therapies brought 
into product development by the pharmaceutical and biotechnology 
sector eventually fail, reflecting negative balance between efficacy and 
adverse effects. 
Appreciating the importance of establishing equilibrium between 
translation and discovery science, Congress recently enacted the Cures 
Acceleration Network (CAN), legislation that will create formal bridges 
between molecular discoveries and new healthcare paradigms. 
Embracing this mandate to facilitate translation encompassed by CAN, 
the leadership of the NIH has created a vigorous path forward by 
constituting a new National Center for Advancing Translational Sciences 
(NCATS). The portfolio for this Center includes advancing novel laboratory-
based discoveries into potential healthcare technologies with reduced 
commercial risk, in order to enhance their attractiveness for future 
development by the private sector.2 This mandate will be accomplished 
by amalgamating programs existing across NIH that can advance the 
development of scientific discoveries to cross the translational divide. 
These resources include the Molecular Libraries Program (MLP) which 
offers high throughput screening capabilities and libraries of compounds 
useful for research and as therapeutics. For example, the Chemical 
Genomics Center, part of MLP, provides a robotic, high throughput 
screening system and a library of >350,000 small molecules to interrogate 
fundamental cellular mechanisms. The Therapeutics for Rare and 
Neglected Diseases program provides resources for preclinical drug 
development centered on rare disorders with limited commercial interest. 
Finally, Clinical and Translational Science Awards offer a nationwide 
platform of institutions with infrastructures of similar nature and a workforce 
that ostensibly, could advance the development of therapeutics through 
patient and community-based studies. Coalescing these resources has 
tremendous potential to foster interactions between public and private 
sectors that optimize the utility of technology cores, minimize risk to lower 
barriers to commercialization, and coordinate transitions across 
communities of practice (e.g., academic-government, government-
pharmaceutical company) that maximize translational efficiencies. 
The genesis of NCATS reflects a modern view of the scientific 
continuum from molecules to global populations. It envisions the advance 
of translation from a discipline focused on new therapies that palliate 
disease, to the quantification of pathobiological risk and disease 
prevention.3 This Center will exploit existing and developing capabilities to 
optimize the evolution of better patient-centered healthcare algorithms. 
Further, NCATS will catalyze collaborations between stakeholders 
emanating from siloed communities within and between  discovery, 
development, and practice, investing them in a public-private partnership 
that is science-based, driving clinical development that enhances 
efficiencies and reduces risks associated with the development of the 
next generation of healthcare solutions. 
Importantly, NCATS will contribute to producing the next generation 
of clinical and translational investigators. Equilibrating the balance 
between discovery and translation requires a cohort of multidisciplinary 
investigators with fluency in the lexicon and paradigms characterizing the 
laboratory and clinic, to enable integration of these broadly different 
domains.4 Also, re-balancing entails a transition in professional culture that 
rewards team science.5 This envisioned future will require the creation of a 
brand for clinical and translational science that attracts novice 
investigators into training programs, to produce the interdisciplinary teams 
which not only maintain the balance between basic and applied science 
but most appropriately, are capable of translating a discovery into 
therapeutic interventions with great promise for good.4, 6, 7 
The creators of NCATS identified clinical pharmacology as one 
foundational element essential to success along the discovery-application 
continuum.8 This recognition highlights clinical pharmacology as one 
discipline at the center of the field of clinical and translational science. 
The key role for clinical pharmacology in this emerging science reflects its 
historic position as the index discipline bridging the laboratory and 
bedside (ie., the translators of translational science). Emanating from the 
most fundamental inquiries into drug actions, clinical pharmacology 
focuses on two elementary questions: What do drugs do to the body? 
and What does the body do to drugs? This concentration on drug action 
and disposition yielded the earliest paradigms of individualized medicine 
in which the right drug is used in the right patient at the right dose.1, 9 
Further, advances in the technologies and approaches emanating from 
the field of pharmacometrics have further positioned clinical 
pharmacologists as domain experts at each node of the continuum of 
drug discovery, development, regulation, and utilization. The continued 
centrality of clinical pharmacology in translational science is evidenced 
by its leadership in key international programs linking the laboratory and 
clinic, including the Pharmacogenomics Research Network10, the Food 
and Drug Administration’s Critical Path Initiative11, and the Institute of 
Medicine’s Committee on Qualification of Biomarkers and Surrogate 
Endpoints in Chronic Disease12. 
While NCATS offers a unique opportunity to energize and further 
develop the firmly established discipline of Clinical Pharmacology in the 
U.S. and many other parts of the world, it is important that these efforts not 
be used as either a tangential or overt attempt to “re-brand” clinical 
pharmacology as the emerging field of clinical and translational 
science.4, 6, 7 Although translation will be closely served by clinical 
pharmacology, especially across the continuum of drug discovery, 
development, regulation, and utilization, these disciplines are intersecting 
as opposed to their being merely co-existent. The core competencies of 
clinical pharmacology, including pharmacogenomics, pharmacokinetics, 
pharmacodynamics, pharmacoepidemiology, pharmacovigilence, and 
pharmacometrics, to name a few, are tools critical to the therapeutic 
translational paradigm. However, they also are essential beyond the 
context of clinical and translational science and they will be applied by 
investigators who self-identify as clinical pharmacologists, but not 
translational investigators. Conversely, core elements of clinical and 
translational science go beyond the facets of clinical pharmacology and 
thus, the portfolio of abilities of translational scientists who are not trained 
in clinical pharmacology, while valuable to the overall effort/goals of 
translational science, may not be complete as applied to addressing the 
intricacies and idiosyncracies of the drug therapy paradigm. The inherent 
risk in re-branding and folding clinical pharmacology into clinical and 
translational science is the possibility of dilution, attrition or loss of those 
central concepts, approaches and techniques that uniquely identify 
clinical pharmacologists as practitioners. The striking contraction of 
experienced investigators in the field of whole animal physiology and 
pharmacology, which were over-shadowed by molecular 
experimentalists, serves as a warning to resist enveloping clinical 
pharmacology as a discipline, into clinical and translational science, least 
we lose the key elements of the former, as a neglected step-child to the 
higher profile elements in clinical and translational science. 
The new National Center for Advancing Translational Sciences 
represents one essential step in advancing the science of translation. It 
consolidates national resources and programs whose integration will 
maximize the discovery-translation continuum. It will crystallize partnerships 
among academic, industry, and government organizations that will 
accelerate the evolution of new insights in molecular pathobiology into 
novel diagnostics and therapeutic tools in the armamentarium available 
for patient care. Further, it will create a professional development path in 
clinical and translational science and medicine that will prepare the 
cadre of specialized investigators invested in the culture of team science. 
This great promise and potential can only be realized in the context of 
solving the great challenges that work to minimize the impact of 
translation on the healthcare of populations: inclusion of broad 
communities of practice, failure rates in drug development, metrics of 
performance, and covering the translational medicine continuum. The 
goal for the new Center is to gain early adoption of the integration of 
discovery science into validated transformational patient-centered 
algorithms to address unmet needs in healthcare. The critical path to 
realizing this goal leverages the core competencies encompassing 
clinical pharmacology as one essential and critical discipline forming the 
foundation for the emerging field of clinical and translational science. The 
clinical pharmacology community embraces this goal and looks forward 
to closely collaborating with NCATS, its leaders, and the diverse 
communities of practice contributing to the discovery-application 
paradigm to translate this vision into a reality that improves the lives of our 
patients. 
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